Table 2 Barriers to the dissemination and implementation of the results of the Magpie Trial results by country group*
Barrier | Number of countries from which at least one representative gave a response | |||
|---|---|---|---|---|
| Â | Low and lower-middle income countries (n = 13#) | Upper-middle income countries (n = 3#) | High-income countries (n = 8#) | Total |
Political barriers | 8 | 2 | 2 | 12 |
Lack of information or awareness regarding magnesium sulphate | 6 | 2 | 1 | 9 |
Costs of treatment | 5 | 2 | 1 | 8 |
Lack of availability of personnel and hospitals | 5 | 1 | 1 | 7 |
Lack of support from public authorities | 4 | 1 | 2 | 7 |
Lack of availability of magnesium sulphate | 5 | 0 | 1 | 6 |
Lack of clinical practice guidelines | 1 | 1 | 3 | 5 |
Magnesium sulphate not registered for treatment of eclampsia/pre-eclampsia | 1 | 1 | 0 | 2 |